A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization.
about
beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2Analysis of fluorescently labeled substance P analogs: binding, imaging and receptor activationBiological and Pharmacological Aspects of the NK1-ReceptorPreferential synaptic relationships between substance P-immunoreactive boutons and neurokinin 1 receptor sites in the rat spinal cordTruncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides.Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation.Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway.Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions.Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individualsSubstance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R)A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomasThe proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complexExpression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathologyTachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77.Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.The role of neuropeptides in adverse myocardial remodeling and heart failure.Substance P Regulation in Epilepsy.Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.Ubiquitin-dependent down-regulation of the neurokinin-1 receptor.Protein kinase C-mediated desensitization of the neurokinin 1 receptor.Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma.Differential expression of functionally identified and immunohistochemically identified NK(1) receptors on sympathetic neurons.Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain.Probing the binding pocket and endocytosis of a G protein-coupled receptor in live cells reported by a spin-labeled substance P agonist.NK1 receptor activation in rat rostral ventrolateral medulla selectively attenuates somato-sympathetic reflex while antagonism attenuates sympathetic chemoreflex.Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.
P2860
Q22253360-C507AFD0-2ABF-486D-B1E6-C60A2B3D7E13Q24799998-D655A3C2-D70D-4766-AF1B-9AF0F66CE646Q26784074-65F8470C-DB73-47DF-A44C-178310079BBCQ33613059-07E3D9A3-CE63-4214-8315-4BF485BB2B27Q34039324-84C24011-5E21-42FA-91DC-B9FCCE848D83Q34150798-7FD8D1A8-60F0-4B09-A0AA-BAD29A62D02EQ34161079-9936AED1-7BE4-41B8-887F-BCE684CDA001Q34591209-68F9753D-1CB9-4F6C-8BED-4E66192D35BEQ35048906-6D8DCAA9-EA68-4955-B59F-8AE826577E3BQ36460037-B824AED7-BA52-4309-908A-4A9B08494620Q36906584-1CD636D6-5106-4A07-8868-EDEE9A8B9CEFQ37062163-E6125D60-E00E-41DD-B95B-4AFDEEEE40B1Q37226704-123F8DCD-3B60-4ED4-A8FE-DC5FE9E7AC16Q37273521-C246F455-B19F-4BD9-91DD-278825E704A2Q37302953-55EDDD56-A38D-44A0-9613-DB7D53268D7DQ37593097-4CE943BB-15BF-4410-9EC9-96F432E2F36AQ38344927-FE1CEDEE-2B15-4EAF-8BF1-D244016D3548Q38531668-0472FEDA-AAE2-4BE3-B333-F326A86A0152Q39093111-7C6C7FDB-F2D6-4817-AD54-2AC9C5270524Q39285392-F5FE264F-A951-45B4-9530-818D6A3C57D5Q40085168-26ED986C-C21A-42C4-989E-63CFA9795356Q40254275-CB684362-0599-4605-9597-E21079C7C6DCQ40814998-449E6F36-E512-4967-9934-6FCF94FB810CQ41618379-FEE26C1F-5383-4DA8-AEE9-D4BD726BEE4DQ43607848-023B7BBB-F45F-4EC1-AF9B-30CB76553FCBQ44444704-D397E281-462D-43C0-89F1-92382CE4D3AAQ44488085-3B5DBAA4-1ED6-490E-9AB5-83254771E8ADQ47843829-625E2B9E-5CA4-4E4F-865D-262336B44E51Q49972918-EFE8E254-F6E6-4F51-9292-4A7E734039D2
P2860
A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
A substance P (neurokinin-1) r ...... resistance to desensitization.
@ast
A substance P (neurokinin-1) r ...... resistance to desensitization.
@en
type
label
A substance P (neurokinin-1) r ...... resistance to desensitization.
@ast
A substance P (neurokinin-1) r ...... resistance to desensitization.
@en
prefLabel
A substance P (neurokinin-1) r ...... resistance to desensitization.
@ast
A substance P (neurokinin-1) r ...... resistance to desensitization.
@en
P2093
P2860
P356
P1476
A substance P (neurokinin-1) r ...... resistance to desensitization
@en
P2093
J E Krause
S E Leeman
W S Saltsman
P2860
P304
P356
10.1073/PNAS.94.17.9475
P407
P50
P577
1997-08-01T00:00:00Z